Amphastar Pharma (AMPH): Raising PT On Opioid Overdose Growth - Piper Jaffray

September 6, 2016 7:52 AM EDT
Get Alerts AMPH Hot Sheet
Price: $16.56 +0.30%

Rating Summary:
    4 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade AMPH Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Piper Jaffray analyst, David Amsellem, reiterated his Overweight rating on shares of Amphastar Pharmaceuticals (NASDAQ: AMPH) after doing a deep dive into company’s naloxone products for opioid overdose. The analyst determined that limited competition outside of the hospital setting (particularly regarding non-injectible products), limited competition within the hospital (only two other consequential naloxone market participants), and the reality of the U.S. opioid epidemic points to high visibility into significant growth for AMPH’s naloxone franchise in 2017+.

The analyst increased his price target to $23 (from $22) on an unchanged 20x multiple applied to 2018 EPS of $1.41, up from $1.34.

For an analyst ratings summary and ratings history on Amphastar Pharmaceuticals click here. For more ratings news on Amphastar Pharmaceuticals click here.

Shares of Amphastar Pharmaceuticals closed at $18.56 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Piper Jaffray

Add Your Comment